Q-omics provides the consensus-scored MEOX1 profile across patient tissues and cancer cell-line models. MEOX1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MEOX1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, MEOX1 RNA expression shows 13,758 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, BLCA, and LUAD as cancer lineages where MEOX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEOX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEOX1 survival associations across molecular data types. MEOX1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEOX1 RNA expression–survival associations across cancer types. High MEOX1 expression shows unfavorable associations in KIRP, ACC and BLCA, but favorable associations in HNSC, BRCA and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for MEOX1 RNA expression.
This table summarizes MEOX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MEOX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEOX1 shows lower tumor expression in BLCA, COAD, HNSC, BRCA, UCEC and KICH. The BLCA box plot shows higher MEOX1 RNA expression in normal versus tumor tissue (log2 FC = −2.440, t-test p < 0.001).
This table shows molecular features associated with MEOX1 in patient tissues and cancer cell lines. In patient samples, MEOX1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MEOX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
